Mar 26 |
Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
|
Mar 26 |
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
|
Mar 26 |
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
|
Mar 26 |
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
|
Mar 25 |
FDA declines to approve Regeneron lymphoma drug odronextamab
|
Mar 25 |
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
|
Mar 25 |
UPDATE 3-Regeneron's blood cancer therapy faces setback as FDA raises trial concerns
|
Mar 25 |
Regeneron Provides Update on Biologics License Application for Odronextamab
|
Mar 22 |
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
|